Things aren't as dire at Roche (OTCQX:RHHBY)
as the market may have you believe, but the reality is the company
needs to deliver strong clinical data from multiple upcoming late-stage
trials. Generics are coming after key drugs that contribute close to 40%
of the company's total revenue, and investors need a reason to believe
again that Roche can continue to generate worthwhile growth as these
veteran contributors start to diminish.
I'm still
more or less bullish on the Tecentriq opportunity at Roche, and I
believe the company has made more progress with its pipeline than is
reflected in the share price. The company definitely needs these
upcoming trial read-outs to go well, but I believe the share price
undervalues what I believe will be long-term mid-single-digit free cash
flow growth.
Read more here:
Roche Drifting Ahead Of Key Data
No comments:
Post a Comment